SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Merkel Peter A.)
 

Sökning: WFRF:(Merkel Peter A.) > Renal Recovery for ...

Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

Cortazar, Frank B. (författare)
St Peters Hosp Albany, NY 12209 USA
Niles, John L. (författare)
Massachusetts Gen Hosp, MA USA
Jayne, David R. W. (författare)
Univ Cambridge, England
visa fler...
Merkel, Peter A. (författare)
Univ Penn, PA USA
Bruchfeld, Annette (författare)
Karolinska Institutet,Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Njurmedicinska kliniken US,Karolinska Inst, Sweden; ChemoCentryx Inc, CA USA
Yue, Huibin (författare)
ChemoCentryx Inc, CA USA
Schall, Thomas J. (författare)
ChemoCentryx Inc, CA USA
Bekker, Pirow (författare)
ChemoCentryx Inc, CA USA
visa färre...
 (creator_code:org_t)
ELSEVIER SCIENCE INC, 2023
2023
Engelska.
Ingår i: KIDNEY INTERNATIONAL REPORTS. - : ELSEVIER SCIENCE INC. - 2468-0249. ; 8:4, s. 860-870
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Introduction: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cyto-plasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 ml/min per 1.73 m2 in the avacopan group and 4.1 ml/min per 1.73 m2 in the prednisone group (P = 0.029) at week 52. This new analysis examines the results in the patient subgroup with severe renal insufficiency at enrollment into the trial, i.e., eGFR <= 20 ml/min per 1.73 m2. Methods: eGFR was determined at baseline and over the course of the trial. Changes in eGFR were compared between the 2 treatment groups. Results: In ADVOCATE, 27 of 166 patients (16%) in the avacopan group and 23 of 164 patients (14%) in the prednisone group had a baseline eGFR <= 20 ml/min per 1.73 m2. At week 52, eGFR increased on average 16.1 and 7.7 ml/min per 1.73 m2 in the avacopan and prednisone groups, respectively (P = 0.003). The last eGFR value measured during the 52-week treatment period was $2-fold higher than baseline in 41% of patients in the avacopan group compared to 13% in the prednisone group (P = 0.030). More patients in the avacopan group versus prednisone group had increases in eGFR above 20, 30, and 45 ml/min per 1.73 m2, respectively. Serious adverse events occurred in 13 of 27 patients (48%) in the avacopan group and 16 of 23 patients (70%) in the prednisone group. Conclusion: Among patients with baseline eGFR <= 20 ml/min per 1.73 m2 in the ADVOCATE trial, eGFR improved more in the avacopan group than in the prednisone group.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Nyckelord

ANCA-associated vasculitis; avacopan; complement; complement 5a receptor; low eGFR; renal recovery

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy